Bilsev Ince, Mehmet Emin Cem Yildirim, Mehmet Dadaci
{"title":"评估维生素D替代对维生素D缺乏症患者基底细胞癌发生和复发率的影响。","authors":"Bilsev Ince, Mehmet Emin Cem Yildirim, Mehmet Dadaci","doi":"10.1007/s12672-019-00365-2","DOIUrl":null,"url":null,"abstract":"<p><p>The study aimed to determine whether 25-OH vitamin D<sub>3</sub> deficiency is present in patients with diagnosed BCC, and the effect of vitamin D replacement on the rates of BCC recurrence in patients with 25-OH vitamin D<sub>3</sub> deficiency. In this prospective study, between 2012 and 2017, in the first stage, 25-OH vitamin D<sub>3</sub> levels of all patients diagnosed with BCC between 2012 and 2013 were evaluated. In the second stage between 2014 and 2015, we evaluated the 25-OH vitamin D<sub>3</sub> level of patients who had 25-OH vitamin D<sub>3</sub> level < 25 ng/mL. All the patients included in the second stage had BCC recurrence. In the third stage, the patients who were diagnosed 25-OH vitamin D<sub>3</sub> deficiency with BCC, between 2015 and 2017, were studied. The mean 25-OH vitamin D<sub>3</sub> level of the patients in the second stage was 10.12 ng/mL. Recurrence was observed in 9.64% of the patients in the second stage. The mean level of serum 25-OH vitamin D<sub>3</sub> in the third stage was 40.1 ng/mL, and 3.49% of these patients presented with recurrence. In all the patients as the initial diagnosis and following the 25-OH vitamin D<sub>3</sub> level in all the patients with BCC recurrence, maintaining 25-OH vitamin D<sub>3</sub> levels above 25 ng/mL can significantly reduce the recurrence rate.</p>","PeriodicalId":13060,"journal":{"name":"Hormones & Cancer","volume":"10 4-6","pages":"145-149"},"PeriodicalIF":3.0000,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12672-019-00365-2","citationCount":"8","resultStr":"{\"title\":\"Assessing the Effect of Vitamin D Replacement on Basal Cell Carcinoma Occurrence and Recurrence Rates in Patients with Vitamin D Deficiency.\",\"authors\":\"Bilsev Ince, Mehmet Emin Cem Yildirim, Mehmet Dadaci\",\"doi\":\"10.1007/s12672-019-00365-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The study aimed to determine whether 25-OH vitamin D<sub>3</sub> deficiency is present in patients with diagnosed BCC, and the effect of vitamin D replacement on the rates of BCC recurrence in patients with 25-OH vitamin D<sub>3</sub> deficiency. In this prospective study, between 2012 and 2017, in the first stage, 25-OH vitamin D<sub>3</sub> levels of all patients diagnosed with BCC between 2012 and 2013 were evaluated. In the second stage between 2014 and 2015, we evaluated the 25-OH vitamin D<sub>3</sub> level of patients who had 25-OH vitamin D<sub>3</sub> level < 25 ng/mL. All the patients included in the second stage had BCC recurrence. In the third stage, the patients who were diagnosed 25-OH vitamin D<sub>3</sub> deficiency with BCC, between 2015 and 2017, were studied. The mean 25-OH vitamin D<sub>3</sub> level of the patients in the second stage was 10.12 ng/mL. Recurrence was observed in 9.64% of the patients in the second stage. The mean level of serum 25-OH vitamin D<sub>3</sub> in the third stage was 40.1 ng/mL, and 3.49% of these patients presented with recurrence. In all the patients as the initial diagnosis and following the 25-OH vitamin D<sub>3</sub> level in all the patients with BCC recurrence, maintaining 25-OH vitamin D<sub>3</sub> levels above 25 ng/mL can significantly reduce the recurrence rate.</p>\",\"PeriodicalId\":13060,\"journal\":{\"name\":\"Hormones & Cancer\",\"volume\":\"10 4-6\",\"pages\":\"145-149\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2019-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s12672-019-00365-2\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hormones & Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12672-019-00365-2\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormones & Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-019-00365-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
Assessing the Effect of Vitamin D Replacement on Basal Cell Carcinoma Occurrence and Recurrence Rates in Patients with Vitamin D Deficiency.
The study aimed to determine whether 25-OH vitamin D3 deficiency is present in patients with diagnosed BCC, and the effect of vitamin D replacement on the rates of BCC recurrence in patients with 25-OH vitamin D3 deficiency. In this prospective study, between 2012 and 2017, in the first stage, 25-OH vitamin D3 levels of all patients diagnosed with BCC between 2012 and 2013 were evaluated. In the second stage between 2014 and 2015, we evaluated the 25-OH vitamin D3 level of patients who had 25-OH vitamin D3 level < 25 ng/mL. All the patients included in the second stage had BCC recurrence. In the third stage, the patients who were diagnosed 25-OH vitamin D3 deficiency with BCC, between 2015 and 2017, were studied. The mean 25-OH vitamin D3 level of the patients in the second stage was 10.12 ng/mL. Recurrence was observed in 9.64% of the patients in the second stage. The mean level of serum 25-OH vitamin D3 in the third stage was 40.1 ng/mL, and 3.49% of these patients presented with recurrence. In all the patients as the initial diagnosis and following the 25-OH vitamin D3 level in all the patients with BCC recurrence, maintaining 25-OH vitamin D3 levels above 25 ng/mL can significantly reduce the recurrence rate.
期刊介绍:
Hormones and Cancer is a unique multidisciplinary translational journal featuring basic science, pre-clinical, epidemiological, and clinical research papers. It covers all aspects of the interface of Endocrinology and Oncology. Thus, the journal covers two main areas of research: Endocrine tumors (benign & malignant tumors of hormone secreting endocrine organs) and the effects of hormones on any type of tumor. We welcome all types of studies related to these fields, but our particular attention is on translational aspects of research. In addition to basic, pre-clinical, and epidemiological studies, we encourage submission of clinical studies including those that comprise small series of tumors in rare endocrine neoplasias and/or negative or confirmatory results provided that they significantly enhance our understanding of endocrine aspects of oncology. The journal does not publish case studies.